Radiation Safety Instructions for Pluvicto™ Information for patients Overview PLUVICTO™ (lutetium Lu-177 vipivotide tetraxetan) is a medication used to treat adults with an advanced cancer called prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer. Due to the radioactive component of this targeted therapy, it is necessary to follow certain precautions in order to limit the exposure to people around you. Although the estimated health risks to the general public are low, these instructions are intended to promote safety and further minimize risk. These instructions are supported by recommendations from international organizations and ensure compliance with State and Federal regulations. Restrictions to be followed after each dose of Pluvicto™ Avoid extended time in public spaces Avoid prolonged close contact with others (approximately 3 feet) Drink plenty of fluids (consult your physician prior) Shower every day following treatment Use toilet in seated position and flush 2-times Clothing and other soiled items should be washed separately from other’s Sleep in a separate bed (at least 3 feet apart) from anyone Return to work Avoid intimate contact with others Restrictions to be followed after completing full Pluvicto™ course Carry patient card for travel (see FAQs) Use effective contraceptive method following the end of treatment
Number of Days 1 2 2 2 2 2 2 1-3 7 Number of Days 60 180
FAQs 1. What if I do not have access to a private bathroom? If you share a bathroom with other people, make sure you are seated and flush the toilet twice after each use. Wipe the toilet seat after each use using a wet wipe or mild soap and water. Take care not to share toiletries. Radiation Safety Instructions for Pluvicto
YNH000479 (03/2026)